Recently, the largest profiling of the global AI in the Drug Discovery industry made to date has been released in the form of an interactive IT-Platform and associated report by Deep Pharma Intelligence, a leading BioTech market research agency focused on sophisticated analytics, benchmarking and forecasting of emerging and frontier domains in the Pharmaceutical, BioTech and Healthcare industries.
The AI in Drug Discovery platform features an interactive database of the Top 100 AI in Drug Discovery Experts, with information-rich profiles on the leading researchers, scientists, entrepreneurs and technologists committed to harnessing the potential of AI to tackle the complex challenges of drug discovery advancement.
Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&D, ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’.
Dr. Chen is a member of the National Academy of Engineering, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Controlled Release Society and a member of the Academy of Distinguished Chemical Engineers at the University of Texas at Austin. Dr. Chen holds a B.S. in Chemical Engineering from UT Austin and an M.S. and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology.
Before joining METiS, Dr. Chen served as Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped found in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench to Phase III clinical trials and FDA approval, and helped to attract significant investments to the company, including an initial public offering in 2017. Prior to Kala, Dr. Chen helped start and build TransForm Pharmaceuticals, which was acquired by Johnson & Johnson in 2005. She had also held various research positions at AstraZeneca and Merck.
